| Literature DB >> 36012694 |
Shuai Wu1,2, Minrong He1,2, Fujin Xia1,2, Xueyi Zhao1,2, Xun Liao1,2, Rongyu Li1,2, Ming Li1,2.
Abstract
Acetamiprid is widely used in paddy fields for controlling Nilaparvata lugens (Stål). However, the risk of resistance development, the cross-resistance pattern and the resistance mechanism of acetamiprid in this pest remain unclear. In this study, an acetamiprid-resistant strain (AC-R) was originated from a field strain (UNSEL) through successive selection with acetamiprid for 30 generations, which reached 60.0-fold resistance when compared with a laboratory susceptible strain (AC-S). The AC-R strain (G30) exhibited cross-resistance to thiamethoxam (25.6-fold), nitenpyram (21.4-fold), imidacloprid (14.6-fold), cycloxaprid (11.8-fold), dinotefuran (8.7-fold), sulfoxaflor (7.6-fold) and isoprocarb (8.22-fold), while there was no cross-resistance to etofenprox, buprofezin and chlorpyrifos. Acetamiprid was synergized by the inhibitor piperonyl butoxide (2.2-fold) and the activity of cytochrome P450 monooxygenase was significantly higher in the AC-R strain compared with the AC-S strain, suggesting the critical role of P450. The gene expression results showed that the P450 gene CYP6ER1 was significantly overexpressed in AC-R compared with the AC-S and UNSEL strains. In addition, the RNA interference (RNAi) of CYP6ER1 significantly increased the susceptibility of AC-R to acetamiprid. Molecular docking predicted that acetamiprid and CYP6ER1 had close binding sites, and the nitrogen atoms had hydrogen bond interactions with CYP6ER1. These results demonstrated that the overexpression of CYP6ER1 contributed to acetamiprid resistance in N. lugens.Entities:
Keywords: Nilaparvata lugens; acetamiprid; cross-resistance; cytochrome P450 monooxygenase; resistance mechanism
Mesh:
Substances:
Year: 2022 PMID: 36012694 PMCID: PMC9409256 DOI: 10.3390/ijms23169429
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
The resistance levels of N. lugens to acetamiprid during the selection process.
| Generation | No. | Slope (±SE) | LC50 (95%CI) (mg/L) | RR | RR’ | ||
|---|---|---|---|---|---|---|---|
| AC-S | 315 | 2.73 (±0.26) | 2.74 (4) | 0.603 | 16.20 (13.65–18.98) | 1 | - |
| G0 | 315 | 2.02 (±0.22) | 1.41 (4) | 0.842 | 39.13 (31.56–47.55) | 2.4 | 1 |
| G1 | 315 | 2.28 (±0.24) | 1.28 (4) | 0.864 | 44.24 (36.75–52.87) | 2.7 | 1.1 |
| G2 | 315 | 1.68 (±0.21) | 2.39 (4) | 0.664 | 40.11 (31.44–53.88) | 2.5 | 1.0 |
| G3 | 270 | 2.30 (±0.35) | 1.40 (3) | 0.706 | 64.47 (52.35–79.10) | 4.0 | 1.7 |
| G4 | 315 | 2.53 (±0.27) | 3.15 (4) | 0.533 | 66.91 (56.03–78.42) | 4.1 | 1.7 |
| G5 | 315 | 1.88 (±0.22) | 5.48 (4) | 0.241 | 69.90 (54.38–86.63) | 4.3 | 1.8 |
| G6 | 270 | 2.45 (±0.32) | 2.71 (3) | 0.438 | 102.22 (80.48–123.93) | 6.3 | 2.6 |
| G7 | 315 | 3.78 (±0.46) | 3.71 (4) | 0.446 | 143.35 (127.85–162.68) | 8.9 | 3.7 |
| G8 | 315 | 2.74 (±0.32) | 0.67 (4) | 0.956 | 165.83 (141.86–194.22) | 10.2 | 4.2 |
| G9 | 315 | 1.71 (±0.20) | 4.58 (4) | 0.644 | 110.35 (86.87–140.56) | 6.8 | 2.8 |
| G10 | 315 | 2.97 (±0.34) | 1.94 (4) | 0.746 | 220.39 (191.08–262.42) | 13.6 | 5.6 |
| G11 | 315 | 3.02 (±0.40) | 1.24 (4) | 0.872 | 125.32 (107.87–144.89) | 7.7 | 3.2 |
| G12 | 315 | 1.64 (±0.24) | 0.96 (4) | 0.915 | 134.95 (107.67–172.07) | 8.3 | 3.5 |
| G13 | 315 | 3.32 (±0.27) | 0.72 (4) | 0.949 | 231.45 (191.95–293.64) | 14.3 | 5.9 |
| G14 | 315 | 1.41 (±0.25) | 1.96 (4) | 0.743 | 271.45 (205.26–414.05) | 16.8 | 6.9 |
| G15 | 315 | 2.06 (±0.30) | 1.78 (4) | 0.775 | 315.42 (263.68–390.67) | 19.5 | 8.1 |
| G16 | 315 | 3.55 (±0.44) | 2.14 (4) | 0.711 | 363.72(325.08–417.12) | 22.5 | 9.3 |
| G17 | 315 | 3.39 (±0.40) | 3.00 (4) | 0.559 | 343.50 (303.20–401.48) | 21.2 | 8.8 |
| G18 | 315 | 2.72 (±0.40) | 2.38 (4) | 0.667 | 421.36 (362.82–519.72) | 26.0 | 10.8 |
| G19 | 315 | 3.28 (±0.47) | 5.86 (4) | 0.210 | 382.19 (336.98–427.66) | 23.6 | 9.8 |
| G20 | 315 | 2.10 (±0.33) | 5.41 (4) | 0.248 | 559.62 (463.01–667.15) | 34.5 | 14.3 |
| G21 | 270 | 4.07 (±0.65) | 6.01 (3) | 0.111 | 858.75 (773.01–983.36) | 53.0 | 22.0 |
| G22 | 315 | 3.44 (±0.49) | 4.00 (4) | 0.406 | 763.95 (674.62–853.34) | 47.2 | 19.5 |
| G23 | 315 | 5.70 (±0.69) | 2.80 (4) | 0.592 | 867.57 (805.36–939.79) | 53.6 | 22.2 |
| G24 | 315 | 2.70 (±0.45) | 1.96 (4) | 0.744 | 769.81 (661.09–880.96) | 47.5 | 19.7 |
| G25 | 270 | 3.87 (±0.48) | 0.87 (3) | 0.833 | 805.16 (718.30–900.54) | 49.7 | 20.6 |
| G26 | 315 | 2.80 (±0.28) | 5.40 (4) | 0.248 | 755.55 (638.24–887.94) | 46.6 | 19.3 |
| G27 | 270 | 2.57 (±0.37) | 6.41 (3) | 0.094 | 730.38 (621.35–888.24) | 45.1 | 18.7 |
| G28 | 315 | 3.06 (±0.33) | 4.28 (4) | 0.370 | 953.99 (833.19–1108.69) | 58.9 | 24.4 |
| G29 | 270 | 2.68 (±0.32) | 3.89 (3) | 0.274 | 793.50 (664.17–953.40) | 49.0 | 20.3 |
| G30 | 315 | 3.37 (±0.38) | 0.66 (4) | 0.956 | 971.23 (861.86–1093.52) | 60.0 | 24.8 |
RR (resistance ratio) = LC50 of acetamiprid-resistant strain/LC50 of susceptible strain. RR’ (resistance ratio) = LC50 of acetamiprid-resistant strain/LC50 of G0.
Cross-resistance of the acetamiprid-resistant strain (G24 and G30) of N. lugens to other insecticides.
| Insecticides | Strains | Slope (±SE) | LC50 (95%CI) mg/L | RR a | CR b | ||
|---|---|---|---|---|---|---|---|
| Acetamiprid | UNSEL | 2.34 (±0.24) | 0.66 (4) | 0.956 | 39.42 (32.61–46.89) | - | |
| G24 | 2.70 (±0.45) | 1.96 (4) | 0.744 | 769.81 (661.09–880.96) | 19.5 | ||
| G30 | 3.37 (±0.38) | 0.66 (4) | 0.956 | 971.23 (861.86–1093.52) | 24.6 | ||
| Thiamethoxam | UNSEL | 1.37 (±0.18) | 6.99 (4) | 0.136 | 32.20 (24.18–45.18) | - | |
| G24 | 3.20 (±0.32) | 2.83 (4) | 0.586 | 722.78 (625.86–826.48) | 22.5 | ||
| G30 | 2.88 (±0.30) | 5.77 (4) | 0.217 | 824.08 (712.78–953.62) | 26.0 | ||
| Nitenpyram | UNSEL | 2.05 (±0.22) | 2.24 (4) | 0.691 | 2.96 (2.40–3.68) | - | |
| G24 | 2.65 (±0.31) | 3.44 (3) | 0.151 | 61.64 (50.49–73.60) | 20.8 | ||
| G30 | 2.30 (±0.26) | 2.29 (4) | 0.665 | 63.20 (51.41–75.36) | 21.4 | ||
| Imidacloprid | UNSEL | 1.91 (±0.26) | 3.64 (4) | 0.457 | 125.54 (110.07–162.34) | ||
| G24 | 2.35 (±0.32) | 2.86 (3) | 0.414 | 1655.61 (1384.60–2051.04) | 13.2 | ||
| G30 | 2.52 (±0.39) | 4.98 (4) | 0.289 | 1837.57 (1571.23–2175.77) | 14.6 | ||
| Cycloxaprid | UNSEL | 1.66 (±0.21) | 2.53 (4) | 0.639 | 14.10 (10.95–18.67) | - | |
| G24 | 2.82 (±0.33) | 4.23 (4) | 0.376 | 159.99 (137.05–186.37) | 11.4 | ||
| G30 | 2.76 (±0.30) | 1.96 (4) | 0.743 | 168.81 (145.55–196.41) | 12.0 | ||
| Dinotefuran | UNSEL | 1.44 (±0.18) | 2.81 (4) | 0.560 | 21.30 (16.04–28.02) | - | |
| G24 | 2.71 (±0.34) | 2.59 (4) | 0.628 | 164.31 (142.28–195.58) | 7.7 | ||
| G30 | 2.63 (±0.29) | 2.02 (4) | 0.732 | 185.93 (159.41–222.21) | 8.7 | ||
| Sulfoxaflor | UNSEL | 2.75 (±0.28) | 1.95 (4) | 0.745 | 7.80 (6.58–9.50) | - | |
| G24 | 3.03 (±0.36) | 1.62 (4) | 0.806 | 40.01 (35.09–46.73) | 5.1 | ||
| G30 | 2.91 (±0.40) | 1.43 (3) | 0.670 | 59.25 (51.32–69.39) | 7.6 | ||
| Clothianidin | UNSEL | 1.55 (±0.19) | 2.52 (4) | 0.640 | 29.81 (23.04–45.18) | - | |
| G24 | 3.28 (±0.42) | 2.01 (3) | 0.570 | 143.64 (124.36–167.85) | 4.8 | ||
| G30 | 2.68 (±0.33) | 4.02 (3) | 0.259 | 151.48 (19.06–181.03) | 5.1 | ||
| Isoprocarb | UNSEL | 2.09 (±0.26) | 1.65 (3) | 0.647 | 77.09 (61.69–95.87) | - | |
| G24 | 2.19 (±0.31) | 5.71 (3) | 0.127 | 602.64 (487.94–733.52) | 7.8 | ||
| G30 | 1.86 (±0.22) | 4.93 (4) | 0.295 | 633.55 (507.88–804.32) | 8.2 | ||
| Chlorpyrifos | UNSEL | 2.77 (±0.37) | 2.23 (3) | 0.526 | 18.99 (16.09–23.64) | - | |
| G24 | 3.82 (±0.45) | 3.50 (3) | 0.321 | 25.45 (22.48–28.61) | 1.3 | ||
| G30 | 2.80 (±0.33) | 6.05 (3) | 0.109 | 32.43 (27.63–38.00) | 1.7 | ||
| Buprofezin | UNSEL | 1.53 (±0.20) | 1.65 (4) | 0.800 | 99.81 (75.78–142.17) | - | |
| G24 | 1.29 (±0.22) | 1.23 (3) | 0.745 | 146.20 (103.14–202.52) | 1.5 | ||
| G30 | 1.70 (±0.23) | 0.20 (3) | 0.978 | 152.44 (118.07–195.39) | 1.5 | ||
| Etofenprox | UNSEL | 1.71 (±0.23) | 3.73 (4) | 0.444 | 121.45 (96.68–157.90) | - | |
| G24 | 1.78 (±0.20) | 0.71 (4) | 0.950 | 110.02 (85.17–138.46) | 0.9 | ||
| G30 | 1.67 (±0.20) | 0.70(4) | 0.951 | 138.67 (108.14–177.42) | 1.1 |
a RR (resistance ratio) = LC50 of acetamiprid-resistant strain/LC50 of the UNSEL strain. b CR (cross-resistance ratio) = LC50 of acetamiprid-resistant strain/LC50 of the UNSEL strain.
Synergistic effects of PBO, TPP and DEM on the acetamiprid to the susceptible and acetamiprid-resistant strain of N. lugens.
| Strain | Acetamiprid/Synergist | Slope (±SE) | LC50 (95%CI) mg/L | SR a | RSR b | ||
|---|---|---|---|---|---|---|---|
| AC-S | Acetamiprid | 2.18 (±0.27) | 0.94 (3) | 0.816 | 27.27 (21.74–33.53) | ||
| Acetamiprid + PBO | 1.93 (±0.25) | 0.19 (3) | 0.980 | 21.00 (15.98–26.21) | 1.3 | ||
| Acetamiprid + TPP | 1.83 (±0.20) | 2.06 (4) | 0.726 | 17.23 (13.58–21.38) | 1.6 | ||
| Acetamiprid + DEM | 2.20 (±0.26) | 1.93 (3) | 0.586 | 26.56 (21.50–32.32) | 1.0 | ||
| AC-R(G28) | Acetamiprid | 3.13 (±0.41) | 3.83 (4) | 0.429 | 1898.71 (1645.95–2237.97) | ||
| Acetamiprid + PBO | 2.11 (±0.24) | 2.91 (4) | 0.572 | 676.31 (535.17–825.02) | 2.8 | 2.2 | |
| Acetamiprid + TPP | 1.47 (±0.20) | 0.97 (4) | 0.442 | 871.68 (662.61–1234.75) | 2.2 | 1.4 | |
| Acetamiprid + DEM | 2.48 (±0.28) | 5.80 (4) | 0.215 | 1685.20 (1434.62–1986.06) | 1.1 | 1.1 |
a SR (synergism ratio) = (LC50 of acetamiprid + acetone)/(LC50 of acetamiprid + synergist); b RSR (relative synergism ratio) = synergism ratio of AC-R (G28) strain/synergism ratio of the AC-S strain.
Figure 1Relative detoxification enzyme activity in the acetamiprid-resistant strain (G28) and susceptible strain (AC-S) of N. lugens. Error bars represent the standard error of the mean. Significant differences between strains were compared with AC-S. * The asterisk indicates significant differences as determined by Student’s t-test (p < 0.05).
Figure 2Relative expression levels of 54 P450 genes in AC-R (G28) compared to AC-S. (A) Relative expression levels of P450 genes from CYP4 clade. (B) Relative expression levels of P450 genes from the CYP2 clade. (C) Relative expression levels of P450 genes from the mitochondrial clade. (D) Relative expiration levels of P450 genes from the CYP3 clade. * The asterisk indicates significant differences as determined by Student’s t-test (p < 0.05).
Figure 3Relative expression levels of CYP6ER1 in AC-R (G28) and UNSEL compared to AC-S. The bars with lowercase letters (a–c) are significantly different according to one-way ANOVA, followed by Tukey’s multiple comparison (p < 0.05).
Figure 4Functional analysis of CYP6ER1 by RNAi. (A) Relative expression of CYP6ER1 in fifth-instar nymphs injected with dsGFP or dsCYP6ER1. (B) Mortality at 96 h of dsRNA-injected fifth-instar nymphs after treatment with acetamiprid (800 mg/L). * The asterisk indicates significant difference between the dsCYP6ER1- and dsGFP-injected groups (Student’s t-test; p < 0.05).
Figure 5The tertiary structure of CYP6ER1 and its docking structure with acetamiprid (A) and dinotefuran (B).
Figure 6Binding pattern of CYP6ER1 with insecticide molecules. (A) the 2D ligand interaction between CYP6ER1 and acetamiprid and (B) its binding pocket; (C) the 2D ligand interaction between CYP6ER1 and dinotefuran and (D) its binding pocket.